Introduction
============

Type 2 diabetes mellitus (T2DM) is a multifactorial disorder characterized by elevation of blood glucose levels due to peripheral insulin resistance. Chronic hyperglycemia \[[@r1]\], over-production of reactive oxygen species, persistent low-grade inflammation and impaired neovascularization \[[@r2]\] are the characteristic features of T2DM that are critically involved in the development of microvascular complications in diabetic patients. Diabetic retinopathy (DR) is one such microvascular complication. DR has an overall prevalence of 22--37% in individuals with known diabetes, and it may lead to blindness due to continuous blood leakage from retinal pericytes and endothelial cells if left untreated \[[@r3]\]. A chronic low-grade subclinical inﬂammation is an important contributor in the pathogenesis of DR \[[@r4]\]. In early stages of DR, loss of microvascular cells creates a hypoxic condition that in turn induces the expression of angiogenic factors \[[@r5]\]. This ischemia-induced retinal neovascularization along with the outgrowth of other retinal membranes gives rise to advanced proliferative diabetic retinopathy (PDR) characterized by loss of vision due to hemorrhage and/or tractional retinal detachment \[[@r6]\]. Other systemic abnormalities common in T2DM, such as hyper-reactivity of platelets, greater prevalence of adhesion molecules, hypercoagulability, and lesser fibrinolysis activity, also contribute to the pathophysiology of DR \[[@r7],[@r8]\].

Several studies have linked a genetic abnormality in the mediators of the innate immune response to the secondary complications of T2DM \[[@r9],[@r10]\]. Toll-like receptors (TLRs), a pattern recognition receptor (PRR) family, are a group of transmembrane receptors and are involved in regulating innate immunity by pathogen recognition \[[@r11]\]. Genetic variations within genes encoding these PRRs have been shown to be involved in several inflammatory diseases \[[@r12]\]. TLR4 is an important member of the TLR family, and its expression has been reported on a variety of cell types, including cardiomyocytes, macrophages, airway epithelium, endothelial, and smooth muscle cells \[[@r13]\]. TLR4 as a PRR has been shown to predominantly interact with microorganism-derived lipopolysaccharides, but other interacting molecules, such as heat shock proteins 60 and 70, ﬁbrinogen, and ﬁbronectin, are also known \[[@r14]\]. After ligand binding, TLR4 takes part in the activation of a pro-inflammatory response by the activation of the nuclear factor-κB pathway. Any deregulation of TLR4 signaling due to the single nucleotide polymorphisms (SNPs) in the extracellular domain of TLR4 may alter the ligand binding capacity and hence disturb the pro- and anti-inflammatory cytokines. Our group has recently shown five TLR4 SNPs, viz [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790), [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791), [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914), to be associated with one of the secondary complications of T2DM \[[@r10]\]. Two of these SNPs, [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) and [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791), are located at exon three of TLR4 in tight linkage disequilibrium. These SNPs have been shown to modulate TLR4 effector functions either by interfering with the binding capacity of TLR4 with its ligands or by controlling the extracellular deposition of functional TLR4 \[[@r15],[@r16]\]. Three other SNPs of TLR4, [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914), have been also reported to be associated with inflammatory diseases, including cancer \[[@r10],[@r17]\].

Buraczynska et al. studied the association of [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) and [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791) SNPs with early onset of DR in a Polish population and found the G allele of rs4986790 SNP to be associated with DR \[[@r18]\]. Zareparsi et al. analyzed the association of these SNPs with age-related macular degeneration, another progressive eye disease leading to loss of vision in elderly patients \[[@r19]\]. The present study was designed to confirm the association of [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) and [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791) with DR in a north Indian cohort. Moreover, we checked the association of three other SNPs [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) with the pathogenesis and progression of DR in a north Indian population for the first time. Since the five studied SNPs belong to the same gene and are located near to each other, there is a possibility of linkage disequilibrium (LD) among them. We checked this possibility by using haplotype analysis.

Methods
=======

Subjects
--------

In this case-control study, a total of 698 individuals, including 378 T2DM patients (M:F = 244:134; Mean age = 51.24±9.62) and 320 age-matched controls (M:F= 182:138; Mean age = 50.13±7.35 years), were consecutively enrolled between July 2010 and December 2013 ([Table 1](#t1){ref-type="table"}). The T2DM patients were subclassified as patients with diabetic retinopathy (128) and DM without retinopathy (250) as additional controls. Recruitment of patients was done by the outpatient department (OPD) clinics of the University Hospital, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. Diabetes was diagnosed according to World Health Organization criteria. Retinopathy was diagnosed according to the Early Treatment Diabetic Retinopathy Study criteria \[[@r20]\]. A total of 320 healthy controls were recruited from the general north Indian population residing in Varanasi. These controls had the same ethnicity, had controlled fasting or postprandial sugar levels, had no family history of T2DM, and were without any other inflammatory or chronic disease. Patients underwent a standardized clinical and laboratory evaluation. Each patient's family history, habits (e.g., smoking, alcoholism), and disease were recorded through a questionnaire. The study was approved by the Institutional Human Ethics Committee of the Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. Informed written consent was obtained from every participant.

###### Biochemical and demographic details of subjects.

  Parameters                                            DR (n=128)         T2DM (n=250)        P value
  ----------------------------------------------------- ------------------ ------------------- ---------
  Average age                                           54.87±8.72 years   51.87±10.57 years   0.05
  Average BMI (kg/m^2^)                                 25±5.1             23.32±4.68          0.13
  Average duration of type 2 diabetes (years)           8.50±6.76          6.08±5.32           0.006
  Male                                                  86 (67.2%)         158 (63.2%)         0.19
  Female                                                42 (32.8%)         92 (53.2%)          0.43
  Poor glycemic Control (according to WHO guidelines)   102 (79.7%)        133 (%)             0.32
  Family history present                                49(38.3%)          45 (18%)            0.64
  Hypertension present (as per WHO guidelines)          32 (25%)           72 (28.8%)          0.5

Biochemical and Demographic parameters of DR patients (n=128) and T2DM (n=250). Data are presented as mean ± SD or as number (percentage).

Genotyping of SNPs by PCR-restriction fragment length polymorphism
------------------------------------------------------------------

Genomic DNA was extracted from 5 ml peripheral blood collected aseptically from median cubital vein in a sodium heparinized syringe using a standard salting-out procedure as per our previous report \[[@r1]\]. The SNPs of the TLR4 gene, [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790), [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791), [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914), were analyzed using PCR restriction fragment length polymorphism (PCR-RFLP) as reported previously \[[@r10]\]. The PCR reaction was set in a total reaction volume of 20 µl containing 50 ng genomic DNA, 5 pmol each primer (Sigma-Aldrich, St Louis, MO), 10 µl 2X DreamTaq PCR Master Mix (Fermentas, Hanover, MD) containing DreamTaq DNA Polymerase, 2X DreamTaq buffer, deoxynucleotide triphosphate (dNTPs) and 4 mmol/L MgCl~2~). PCR thermal cycling was done on Applied Biosystems Veriti 96-well Thermal Cycler. The sequence of the implicated primers used in the study and the methodology adopted is summarized in [Table 2](#t2){ref-type="table"}. The PCR set-up was composed of an initial denaturation step of 5 min followed by 35 cycles of 40 s at 94 °C, 45 s at 58 °C, and 40 s at 72 °C. This was followed by a final extension step of 10 min. The amplified products of SNPs [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790), [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791), [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) were digested with the restriction enzymes *BccI*, *BslI*, *KpnI*, *StyI, and SphI,* respectively. The digested products were separated on 3% agarose gel ([Figure 1](#f1){ref-type="fig"}).

###### PCR conditions for TLR4 SNPs genotyping.

  SNP ID                                                           Primers (5'-3')            Restriction enzyme used   Product size and genotypes
  ---------------------------------------------------------------- -------------------------- ------------------------- -----------------------------------
  [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790)     F: CTGCTCTAGAGGGCCTGTG     BccI                      140=AA 140, 77, 63=AG 77, 63=GG
  R: TTCAATAGTCACACTCACCAG                                                                                              
  rs4986791                                                        F: CTACCAAGCCTTGAGTTTCTG   BslI                      110=TT 110, 89, 22=TC 89, 22=CC
  R: AAGCTCAGATCTAAATACT                                                                                                
  [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931)   F: ATAACCTCAGTGGGCTCTGG    KpnI                      241=AA 241, 190, 51=AG
  R: ATGTTCTGGCATCTGGGAAG                                                                                               
  [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911)     F: TCACTTTGCTCAAGGGTCAA    StyI                      203=TT 203, 178, 25=TC 178, 25=CC
  R: AAACCTGCATGCTCTGCAC                                                                                                
  [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914)     F: ACAAAATGGTCCCTCACAGC    SphI                      150=TT 157, 90, 67=TC 90, 67=CC
  R: TGGAAAGTAGCAAGTGCAATG                                                                                              

Primers for PCR-RFLP of the TLR4, Restriction Enzymes used and base pair products for genotypes.

![Gels showing PCR-RFLP analysis of different SNPs of the TLR4 gene. The amplified products of the SNPs [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790), [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791), [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) were digested with restriction enzymes *BccI*, *BslI*, *KpnI*, *StyI and SphI*, respectively. The restricted products were separated on 3% agarose gel, according to our previous report \[[@r10]\]. **A**: For genotyping [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790), the 140-bp PCR product was digested with BccI. The A allele is not cut by the enzyme, whereas the G allele yields 77 and 63 bp products. **B**: For genotyping [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791), the 110-bp PCR product was digested with BslI. The T allele is not cut by the enzyme, whereas the C allele yields 89 and 21 bp products. **C**: For genotyping [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), the 203-bp PCR product was digested with StyI. The T allele is not cut by the enzyme, whereas the C allele yields 178 and 25 bp products. **D**: For genotyping [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), the 241-bp PCR product was digested with KpnI. The A allele is not cut by the enzyme, whereas the G allele yields 190 and 51 bp products. **E**: For genotyping [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914), the 157-bp PCR product was digested with SphI. The T allele is not cut by the enzyme, whereas the C allele yields 90 and 67 bp products.](mv-v20-704-f1){#f1}

Statistical analysis for genotype comparison
--------------------------------------------

The allele and genotypic distributions among the groups were evaluated using the χ^2^ test. The differences in the frequencies between the case and the control groups were analyzed for statistical significance at the 95% confidence interval (CI) using the χ^2^ test. The allele frequencies of all SNPs were in Hardy--Weinberg equilibrium. Odds ratios (ORs) were calculated and reported within the 95% confidence limits using a calculator for CIs of ORs based on the null hypothesis ([Confidhypo](http://www.hutchon.net/ConfidORnulhypo.htm)). A two-tailed p value of ≤0.05 was considered statistically significant.

Linkage disequilibrium and haplotype analysis
---------------------------------------------

Haplotype frequencies and LD were calculated using Haploview software (version 4.2; [The Broad Institute](http://www.broadinstitute.org)) based on the expectation--maximization (EM) algorithm. This program takes one haplotype at a time and compares its frequency between cases and controls. The standardized disequilibrium coefficient (D') and correlation coefficient (r^2^) between these SNPs were also analyzed using the LD plot function of this software to find certain allelic combinations of SNPs that might alter the risk of DR. A p value \<0.05 was considered statistically significant for the observed haplotypes.

Results
=======

A comparison of clinical and biochemical characteristics of the study subjects revealed that subjects with DR were older in age compared to T2DM subjects (54.87±8.72 and 51.87±10.57 years, respectively; p = 0.05; [Table 1](#t1){ref-type="table"}). Duration of diabetes was significantly higher in DR cases compared to T2DM cases (8.50±6.76 years for DR, 6.08±5.32 years for T2DM; p = 0.006). The remaining parameters did not vary significantly between the two groups. The genotypes of TLR4 SNPs [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790), [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791), [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) were analyzed in 378 T2DM patients and 320 age-matched controls. Genotypic frequencies of all TLR4 SNPs studied were similar to those reported for other populations \[[@r21],[@r22]\].

The association of TLR4 SNPs was analyzed in the combined T2DM group and compared to the controls. For TLR4 [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) SNP, the prevalence of homozygous risk genotype GG was 0.5% in the combined T2DM group while it was absent in healthy controls ([Table 3](#t3){ref-type="table"}). Interestingly, for TLR4 [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791) SNP, the risk genotype CC showed a higher prevalence in controls (1.2%) compared to the combined T2DM group (0.8%; p value \>0.05). The genotypic frequencies of risk genotypes of [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) were 0.3%, 4.2%, and 8.5%, respectively, in the combined T2DM cases compared to 0.9%, 0.6%, and 13.8% in controls. Genotypic frequencies of all SNPs were found to be in Hardy--Weinberg equilibrium for both study groups.

###### Observed genotype frequencies for studied SNPs among T2DM cases.

  SNP and genotype                                                                          Controls, no., (%)   T2DM, no., (%)   OR     95% CI          p- value
  ----------------------------------------------------------------------------------------- -------------------- ---------------- ------ --------------- ----------
  [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) (TLR4_Asp299Gly) 119515123                                                                
  AA                                                                                        247 (77.2)           287 (76.0)       --     --              --
  AG                                                                                        73 (22.8)            89 (23.5)        1.01   0.71 to 1.44    0.93
  GG                                                                                        0 (0)                2 (0.5)          6.2    0.38 to 101.4   0.19
  AG + GG                                                                                   73 (22.8)            91 (24.1)        1.01   0.71 to 1.44    0.84
  [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791) (TLR4_Thr399Ile) 119515423                                                                
  CC                                                                                        262 (81.9)           302 (79.9)       --     --              --
  CT                                                                                        54 (16.9)            73 (19.3)        1.17   0.79 to 1.72    0.42
  TT                                                                                        4 (1.2)              3 (0.8)          0.65   0.14 to 2.89    0.57
  CT + TT                                                                                   58 (18.1)            76 (20.1)        1.13   0.77 to 1.65    0.35
  [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931) (TLR4_1859) 120464147                                                                   
  AA                                                                                        173 (54.1)           183 (48.4)       --     --              --
  AG                                                                                        144 (45.0)           194 (51.3)       1.26   0.93 to 1.70    0.12
  GG                                                                                        3 (0.9)              1 (0.3)          0.34   0.04 to 2.48    0.29
  AG + GG                                                                                   147 (46.0)           195 (51.6)       1.25   0.92 to 1.67    0.14
  [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) (TLR4_2437) 120464725                                                                     
  TT                                                                                        184 (57.5)           181 (47.9)       --     --              --
  TC                                                                                        134 (41.9)           181 (47.9)       1.37   1.01 to 1.85    0.04
  CC                                                                                        2 (0.6)              16 (4.2)         4.8    1.86 to 12.36   0.001
  TC + CC                                                                                   136 (42.5)           197 (52.1)       1.46   1.09 to 1.97    0.001
  [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911) (TLR4_7764) 120470054                                                                     
  CC                                                                                        112 (35.0)           177 (46.8)       --     --              --
  CT                                                                                        164 (51.2)           169 (44.7)       0.65   0.47 to 0.89    0.008
  TT                                                                                        44 (13.8)            32 (8.5)         0.45   0.27 to 0.76    0.002
  CT + TT                                                                                   212 (66.3)           201 (53.2)       0.6    0.44 to 0.81    0.001

Genotype frequencies of single nucleotide polymorphisms (SNPs) [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790), [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791), [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911) and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) of TLR4 gene among T2DM and controls

In the T2DM group, 128 patients were diagnosed with DR. The distribution of genotypes of TLR4 SNPs in these DR patients compared to control subjects is documented in [Table 4](#t4){ref-type="table"}. The frequency of risk genotype GG of [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) was found to be 0.8% in DR cases. The combined risk genotypes (GG + AG) of [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) were found to be evenly distributed in the DR cases (22.7%) compared to controls (22.8%; OR 0.99, 95% CI 0.61--1.61). The risk genotype TT of [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791) was absent in DR. The combined risk genotype CT + TT of the TLR4 SNP [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791) polymorphism was also higher in DR cases (20.3%) than in controls (18.1%; OR 1.15, 95% CI 0.68--1.95). For TLR4 SNP [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), both the heterozygous genotype AG and the combined risk genotypes AG + GG were significantly associated with DR with respect to controls (OR 1.53, 95% CI 1.01--2.31, p = 0.04 for AG; OR 1.50, 95% CI 0.99--2.26, p = 0.05 for AG + GG). For TLR4 [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914), the heterozygous genotype CT along with the combined risk genotype CT + TT were significantly associated with DR compared to controls (OR 1.48, 95% CI 1.00--2.25, p = 0.05 for CT; OR 1.48, 95% CI 1.0--2.24, p = 0.05 for CT + TT). For [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), the frequency of risk genotype TT was slightly but not significantly lower in DR (7.8%) compared to controls (13.8%; OR 0.77, 95% CI 0.26--1.03).

###### Observed Genotype frequencies for studied SNPs among DR cases.

  SNP and genotype                                                                          Controls, no., (%)   DR, no., (%)   OR     95% CI          p- value
  ----------------------------------------------------------------------------------------- -------------------- -------------- ------ --------------- ----------
  [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) (TLR4_Asp299Gly) 119515123                                                              
  AA                                                                                        247 (77.2)           99 (77.4)      --     --              --
  AG                                                                                        73 (22.8)            28 (21.8)      0.95   0.58 to 1.56    0.86
  GG                                                                                        0 (0)                1 (0.8)        --     --              --
  AG + GG                                                                                   73 (22.8)            29 (22.7)      0.99   0.61 to 1.61    0.97
  [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791) (TLR4_Thr399Ile) 119515423                                                              
  CC                                                                                        262 (81.9)           102 (79.7)     --     --              --
  CT                                                                                        54 (16.9)            26 (20.3)      1.24   0.72 to 2.12    0.42
  TT                                                                                        4 (1.2)              0 (0)          0.24   0.02 to 2.23    0.21
  CT + TT                                                                                   58 (18.1)            26 (20.3)      1.15   0.68 to 1.95    0.59
  [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931) (TLR4_1859) 120464147                                                                 
  AA                                                                                        173 (54.1)           56 (43.7)      --     --              --
  AG                                                                                        144 (45.0)           72 (56.3)      1.53   1.01 to 2.31    0.04
  GG                                                                                        3 (0.9)              0 (0)          0.26   0.02 to 3.74    0.32
  AG + GG                                                                                   147 (46.0)           72 (56.3)      1.5    0.99 to 2.26    0.05
  [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) (TLR4_2437) 120464725                                                                   
  TT                                                                                        184 (57.5)           61 (47.7)      --     --              --
  TC                                                                                        134 (41.9)           66 (51.5)      1.48   1.00 to 2.25    0.05
  CC                                                                                        2 (0.6)              1 (0.8)        1.56   0.11 to 21.58   0.73
  TC + CC                                                                                   136 (42.5)           67 (52.3)      1.48   1.00 to 2.24    0.05
  [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911) (TLR4_7764) 120470054                                                                   
  CC                                                                                        112 (35.0)           52 (40.6)      --     --              --
  CT                                                                                        164 (51.2)           66 (51.5)      0.86   0.55 to 1.34    0.51
  TT                                                                                        44 (13.8)            10 (7.8)       0.52   0.26 to 1.03    0.06
  CT + TT                                                                                   212 (66.3)           76 (59.4)      0.77   0.50 to 1.17    0.22

Genotype frequencies of single nucleotide polymorphisms (SNPs) [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790), [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791), [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911) and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) of TLR4 gene among DR and controls.

It has previously been shown that some of the TLR4 SNPs reside in strong LD in normal tension glaucoma, another eye-related disease \[[@r23]\]. To estimate haplotype frequencies and analyze the haplotype association with DR, we selected five SNPs---[rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790), [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791), [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914)---for LD and haplotype analysis ([Table 5](#t5){ref-type="table"}, [Figure 2](#f2){ref-type="fig"}). The SNPs [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) and [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791)were found not to be in significant LD (D' = 0.05, LOD = 0.0, confidence bound 0.01--0.82, r^2^ = 0.0). Evidence of intermediate LD was found between loci [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931) and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) (D' = 0.24, LOD = 2.67, confidence bound 0.12--0.33, r^2^ = 0.051) and between loci [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) and [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911) (D' = 0.37, LOD = 4.75, confidence bound 0.24--0.49, r^2^ = 0.069). No significant LD was found between loci [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931) and [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911) (D' = 0.155, LOD = 0.73, confidence bound 0.02--0.29, r^2^ = 0.013). Fourteen haplotypes were identified having a frequency of more than 1% ([Table 6](#t6){ref-type="table"}). Haplotypes ACATC (37.5%) and ACATT (14.8%) were the two most common haplotypes obtained.

###### Haplotype analysis for the studied SNP markers.

  L1                                                                   L2                                                             D       LOD    R**^2^**   CI low   CI high   Dist   T-int
  -------------------------------------------------------------------- -------------------------------------------------------------- ------- ------ ---------- -------- --------- ------ -------
  [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790)         [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791)   0.051   0      0          0.01     0.82      300    0
  [rs**10759931**](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931)   [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914)   0.236   2.67   0.051      0.12     0.33      578    3.4
  [rs**10759931**](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931)   [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911)   0.155   0.73   0.013      0.02     0.29      5907   \-
  [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914)         [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911)   0.371   4.75   0.069      0.24     0.49      5329   5.48

The table describes the LD value calculated for the all present SNPs of TLR4 gene. L1 and L2 are loci in question, D\' is the value of D prime between the two loci, LOD is the log of the likelihood odds ratio, r^2^ is the correlation coefficient between the two loci, CI low is 95% confidence lower bound on D\', CI high is the 95% confidence upper bound on D\', Dist is the distance (in bases) between the loci, and is only displayed if a marker info file has been loaded, T-int is a statistic used by the HapMap Project to measure the completeness of information represented by a set of markers in a region.

![Linkage disequilibrium plot. Haplotype frequencies and LD were calculated using Haploview software (version 4.2). The LD parameter D is represented by the specific value in each cell. The cells are color graduated representing the strength of LD between the two markers. The rs numbers are SNP IDs extracted from the [Ensembl](http://www.ensembl.org) database. The loci [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) are in intermediate LD.](mv-v20-704-f2){#f2}

###### Association status of common haplotypes of TLR4 gene with DR.

  Haplotype   Frequency   Case, control frequencies   Chi square   p value
  ----------- ----------- --------------------------- ------------ ---------
  ACATC       0.375       0.374, 0.379                0.019        0.89
  ACATT       0.148       0.155, 0.120                1.363        0.243
  ACGTC       0.074       0.073, 0.081                0.135        0.713
  ACACC       0.039       0.038, 0.042                0.06         0.806
  ACGCT       0.045       0.041, 0.060                1.235        0.266
  ATATC       0.044       0.043, 0.045                0.012        0.912
  GCATC       0.037       0.041, 0.023                1.34         0.247
  GCGTT       0.018       0.019, 0.013                0.29         0.589
  ACACT       0.052       0.052, 0.053                0.004        0.953
  ATACT       0.014       0.013, 0.019                0.349        0.555
  ACGTT       0.043       0.041, 0.049                0.218        0.641
  ACGCC       0.024       0.023, 0.029                0.254        0.614
  ATGCT       0.01        0.009, 0.016                0.717        0.397
  GCACT       0.02        0.019, 0.024                0.164        0.685

Fourteen haplotypes with a frequency of more than 1% was found.

Discussion
==========

Persistent hyperglycemia and oxidative stress in T2DM are shown to elicit the innate immune system and chronic low-grade inflammation in patients \[[@r9]\]. DR is also an inflammatory disease having a multigenic etiology and is shown to be regulated by inadequate activation of members of the immune system \[[@r18]\]. TLRs are important contributors to the innate immune system, and some members of the TLR family, especially TLR4, have been implicated in several inflammatory and immune disorders \[[@r24]\]. Therefore, SNPs, even with comparatively small ORs in the *TLR4* gene, when combined can cause alterations in protein functioning that may contribute, to a moderate degree, to the development of DR.

The association of two SNPs included in this study, [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) and [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791), have been widely studied in inflammatory diseases, such as Crohn's disease, and gastric cancer and gastric lymphoma in different cohorts, including Indians \[[@r25],[@r26]\]. Recently, Buraczynska et al. also associated these two SNPs with early onset of DR in a Polish population \[[@r18]\]. The present study was designed to observe the genotypic frequencies of [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) and [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791) in a north Indian population to observe the ethnic and population variations of TLR4 polymorphism. The risk genotype GG of [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) was found to be present only in T2DM cases while it was absent in the control group, similar to the results of Buraczynska et al. \[[@r18]\]. Although the combined risk genotype (CT + TT) of TLR4 [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791) was greater in the DR group compared to controls, we were unable to find any risk genotype TT in the DR group. Our data suggested neither of these TLR4 SNPs were associated with DR in an Indian population. This observation differs from that of Buraczynska et al. \[[@r18]\] who found the risk allele of TLR4 SNP [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) to be associated with early onset of DR in a Polish population. The difference in ethnic and racial backgrounds of Polish and Indian populations or disease heterogeneity may be the reason for this observed variation. Moreover, stratification of subjects on the basis of age of onset of DR by Buraczynska et al. might be another reason for this observed variance between these two studies. The study of Buraczynska et al. focused on cases with a comparatively early onset, suggesting stronger involvement of genetic factors. However, our study was focused on the general risk for DR patients, regardless of age. Moreover, differences in the interactive effects of environment and lifestyle of Polish and Indian populations can't be ruled out.

We then analyzed the association of [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931), [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) variants of TLR4 with DR in our population. We found the heterozygous genotype AG of [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931) and the combined risk genotype (AG + GG) to be significantly associated with the development of DR in an Indian population. The risk allele A of this variant exhibits altered binding affinity with transcription factors, thereby resulting in a lower expression of TLR4 \[[@r27]\]. Hence, low expression of TLR4 mediated by this variant could explain the different susceptibility of various diseases, including cancer, among different ethnic groups \[[@r10],[@r17]\]. A similar trend in association was found for variant [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) as both heterozygous genotype TC and combined risk genotype (TC + CC) were significantly associated with the pathogenesis of DR. This finding was supported by our previous report that heterozygous genotypes of TLR4 variant [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) are common in the Indian population \[[@r10]\]. Suh et al. (2011) found no significant association of [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) with normal tension glaucoma in a South Korean population \[[@r28]\]. A possible explanation for this contradictory result is the ethnic differences between study subjects and disease heterogeneity. Another difference was in the number of study participants. The Korean study comprised 527 individuals, while our study analyzed 690 Indian subjects. For TLR4 variant [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911), we found the risk genotype TT to be marginally but not significantly lower in the DR group compared to control subjects, a finding in agreement with Suh et al. (2011) for a South Korean population \[[@r28]\]. Haplotype analysis for the calculation of LD for the five SNPs of the TLR4 gene yielded 14 haplotypes having a frequency of more than 1%. The two loci combinations [rs10759931](http://www.ncbi.nlm.nih.gov/snp/?term=rs10759931) and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914), and [rs1927914](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927914) and [rs1927911](http://www.ncbi.nlm.nih.gov/snp/?term=rs1927911) were found to be in intermediate LD. The other TLR4 SNP loci combinations in our population showed no sign of LD among them. Association analysis using haplotypes showed none of the haplotypes were associated with either susceptibility or resistance to DR in a north Indian population.

Data regarding the role of TLR4 gene polymorphism in diabetic complication are scarce. Only a few reports document an association of TLR4 with a secondary complication of diabetes. Rudofsky et al. associated the TLR4 SNPs [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) and [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791) with a reduced prevalence of diabetic neuropathy in type 2 diabetes \[[@r29]\]. Our group associated TLR4 variants with impairment of wound healing in T2DM patients \[[@r10]\], and only one report associated SNPs [rs4986790](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986790) and [rs4986791](http://www.ncbi.nlm.nih.gov/snp/?term=rs4986791) with DR in the Polish population \[[@r18]\]. Hence, our study is a step toward improving our understanding of the missing link between innate immunity, T2DM, and its complications, such as DR. Further studies with different ethnic groups will demonstrate whether the same results can be obtained in other areas of the Indian subcontinent.

This work was funded by the Department of Science and Technology, New Delhi, India (P-07-523). Financial assistance by the Department of Biotechnology, Ministry of Science and Technology, New Delhi, in the form of a Senior Research Fellowship to the first author is thankfully acknowledged.
